ArticleSmall science2024
Nanocomposite Hydrogels: A Promising Approach for the Treatment of Degenerative Joint Diseases.
Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antioxidant Nanotherapies for Intervertebral Disk Degeneration: Progress and Prospects.Antioxidants (Basel, Switzerland) · 2026Review
- Engineering extracellular matrix-based hydrogels for intervertebral disc regeneration.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative joint diseases, as a global public health issue, impose significant burdens on patients' lives and substantial economic costs on society. Currently, the primary modalities include physical therapy, pharmaceutical intervention, and surgical procedures. None of these approaches can alter the course of this degenerative process. Due to their commendable biocompatibility, biodegradability, and heightened efficacy in drug delivery, hydrogels present themselves as a novel noninvasive remedy for degenerative joint ailments. However, the clinical application of hydrogels still faces some challenges, including the uncontrolled discharge of encapsulated medications, the absence of adequate mechanical reinforcement for destabilized joints, and adaptability to fluctuating microenvironments. Recently, nanocomposite hydrogels, formed by introducing nanomaterials into hydrogels by physical or chemical means, can improve the limitations of hydrogels and extend their potential for biological applications in degenerative joint diseases. In this study, the pathologic features of degenerative joint diseases and the multiple applications of different types of nanocomposite hydrogels in targeting these different pathologic features are briefly described. It also concludes with an outlook on the use of nanocomposite hydrogels in clinical settings and discusses their challenges and limitations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.